Heron Therapeutics, Inc. /DE/ Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Morgan Adam, was filed 12 Aug 2025.
Heron Therapeutics, Inc. /DE/: what insiders have been doing
Heron Therapeutics, Inc. /DE/ belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). Over the twelve months to 3 November 2026, 60 filings were filed, from 10 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
With 60 filings in twelve months, the company is more active than the median of 24 filings across the 3,178 companies we follow on the same exchange. The full history, which starts in 2006, counts 52 purchases against 49 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 154.9 m USD and net income at -20.2 m USD.
There has been no open-market purchase by an insider of Heron Therapeutics, Inc. /DE/ for at least a year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -76.4%Entry US$1.40 · Close at T+365 US$0.33
- -76.4%Entry US$1.40 · Close at T+365 US$0.33
- -22.6%Entry US$1.37 · Close at T+365 US$1.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 50,021 sharesCommon StockSEC:0001193125-26-444851:0
- 12,181 shares@ US$0.28Common StockSEC:0001193125-26-444851:1
- 34,788 sharesCommon StockSEC:0001193125-26-444851:2
- 8,471 shares@ US$0.28Common StockSEC:0001193125-26-444851:3
- 13,535 sharesCommon StockSEC:0001193125-26-444847:0
- 3,850 shares@ US$0.28Common StockSEC:0001193125-26-444847:1
- 11,695 sharesCommon StockSEC:0001193125-26-444847:2
- 3,327 shares@ US$0.28Common StockSEC:0001193125-26-444847:3
- 11,770 sharesCommon StockSEC:0001193125-26-444842:0
- 3,349 shares@ US$0.28Common StockSEC:0001193125-26-444842:1
- 11,695 sharesCommon StockSEC:0001193125-26-444842:2
- 3,327 shares@ US$0.28Common StockSEC:0001193125-26-444842:3
- 11,770 sharesCommon StockSEC:0001193125-26-444831:0
- 3,349 shares@ US$0.28Common StockSEC:0001193125-26-444831:1
- 1,102 shares@ US$0.360.0006% mcap0.5% of flowCommon StockSEC:0001193125-26-427545:1
- 3,874 sharesCommon StockSEC:0001193125-26-427545:0
- 3,874 sharesCommon StockSEC:0001193125-26-427542:0
- 13,797 sharesCommon StockSEC:0001193125-26-427524:0
- 1,102 shares@ US$0.360.0006% mcap0.5% of flowCommon StockSEC:0001193125-26-427542:1
- 3,360 shares@ US$0.360.0018% mcap0.8% of flowCommon StockSEC:0001193125-26-427524:1
- 31,250 sharesCommon StockSEC:0001193125-26-341528:0
- 8,888 shares@ US$0.500.0079% mcap100.0% of flowCommon StockSEC:0001193125-26-341528:1
- 11,694 sharesCommon StockSEC:0001193125-26-329720:2
- 11,769 sharesCommon StockSEC:0001193125-26-329848:0
- 50,021 sharesCommon StockSEC:0001193125-26-329694:0
25 of 497 declarations
About Heron Therapeutics, Inc. /DE/
HERON THERAPEUTICS, INC. is a biopharmaceutical company focused on developing treatments for pain and nausea. It is listed on NASDAQ under the ticker HRTX.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
